Melo, Miguel
Gavina, Cristina
Silva-Nunes, José
Andrade, Luís
Carvalho, Davide
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 1 April 2021
Accepted: 9 July 2021
First Online: 27 July 2021
Declarations
:
: Not applicable.
: Not applicable.
: MM participated in advisory board meetings and received speaker’s fees from the following companies: AstraZeneca, Bial, Boeringher-Ingelheim, Lilly, NovoNordisk and Sanofi. CG reports consulting and speaking fees from Astrazeneca, Novo Nordisk, Lilly, Boheringer Ingelheim, MSD and Bayer. JSN reports receiving research funding from AstraZeneca, and Merck sa; and consulting/speaker’s fees from Abbott, AstraZeneca, Bial, Boehringer Ingelheim, Janssen, Lilly, Medinfar, Merck sa, Merck Sharp & Dohme, Mundipharma, Novartis, Novo Nordisk, Roche, Sanofi, Servier, Tecnimede. LA reports membership of advisory board, consultancy/ speaker's fees from: Astra-Zeneca, Lilly, Bhoeringer, NovoNordisk and Bial.DC is member of Advisory Boards of Novo-Nordisk, Astra-Zeneca, Eli Lilly, Sanofi-Aventis and is speaker for Novo-Nordisk, Astra-Zeneca, Eli Lilly.